What is the optimal therapy for young males with hypogonadotropic hypogonadism?

Clinical Endocrinology

Volumn 72, Issue 6, 2010, Pages 731-737

  Han, T S ^a   Bouloux, P M G ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANDROSTANOLONE; CHORIONIC GONADOTROPIN; GONADORELIN; GONADOTROPIN DERIVATIVE; HUMAN MENOPAUSAL GONADOTROPIN; MENOPURS; RECOMBINANT FOLLITROPIN; RECOMBINANT GROWTH HORMONE; TAMOXIFEN; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE; TOSTRAN; UNCLASSIFIED DRUG; GONADOTROPIN;

ACNE; ADJUVANT THERAPY; ADULT; AGGRESSION; ANDROGEN THERAPY; BEDTIME DOSAGE; BREAST HYPERTROPHY; BREAST TENDERNESS; CASE REPORT; CRYPTORCHISM; DELAYED PUBERTY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; EVENING DOSAGE; FERTILIZATION IN VITRO; FOLLITROPIN BLOOD LEVEL; GYNECOMASTIA; HAIR LOSS; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERSEXUALITY; HYPOGONADOTROPIC HYPOGONADISM; INTRACYTOPLASMIC SPERM INJECTION; KALLMANN SYNDROME; LIPID BLOOD LEVEL; LOADING DRUG DOSE; LOCAL SKIN REACTION; LOWER URINARY TRACT SYMPTOM; LUTEINIZING HORMONE BLOOD LEVEL; MALE; MALE INFERTILITY; MOOD DISORDER; NUCLEAR MAGNETIC RESONANCE IMAGING; ORCHIDOPEXY; POLYCYTHEMIA; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE HYPERTROPHY; REVIEW; SEBORRHEA; SEXUAL MATURATION; SIDE EFFECT; SPERMATOGENESIS; SPERMATOZOON DENSITY; TESTIS SIZE; TESTOSTERONE BLOOD LEVEL; ADOLESCENT; CALIBRATION; DRUG EFFECTS; ENDOCRINOLOGY; EVALUATION STUDY; FERTILITY; HORMONE SUBSTITUTION; HYPOGONADISM; INFANT; PHYSIOLOGY; PROCEDURES; STANDARDS;

ADOLESCENT; ADULT; CALIBRATION; ENDOCRINOLOGY; FERTILITY; GONADOTROPIN-RELEASING HORMONE; GONADOTROPINS; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; INFANT; MALE; SPERMATOGENESIS; TESTOSTERONE;

EID: 77952641591     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2009.03746.x     Document Type: Review

References (38)

1. Hardelin, J.P. Dodé, C. (2008) The complex genetics of Kallmann syndrome: KAL1, FGFR1, FGF8, PROKR2, PROK2, et al. Sexual Development, 2, 181 193.
2. Wu, F. Srinivas-Shankar, U. (2005) Testosterone replacement therapy. Medicine, 33, 41 43.
3. Lala, R., Matarazzo, P., Chiabotto, P. et al. (1997) Early hormonal and surgical treatment of cryptorchidism. Journal of Urology, 157, 1898 1901.
4. Rajfer, J., Handelsman, D.J., Swerdloff, R.S. et al. (1986) Hormonal therapy of cryptorchidism. A randomized, double-blind study comparing human chorionic gonadotropin and gonadotropin-releasing hormone. New England Journal of Medicine, 314, 466 470.
5. Kaleva, M. Toppari, J. (2005) Cryptorchidism: an indicator of testicular dysgenesis? Cell and Tissue Research, 322, 167 172.
6. Thorsson, A.V., Christiansen, P. Ritzén, M. (2007) Efficacy and safety of hormonal treatment of cryptorchidism: current state of the art. Acta Paediatrica, 96, 628 630.
7. Ritzén, E.M., Bergh, A., Bjerknes, R. et al. (2007) Nordic consensus on treatment of undescended testes. Acta Paediatrica, 96, 638 643.
8. Kollin, C., Karpe, B., Hesser, U. et al. (2007) Surgical treatment of unilaterally undescended testes: testicular growth after randomization to orchiopexy at age 9 months or 3 years. Journal of Urology, 178, 1589 1593.
9. Vernaeve, V., Krikilion, A., Verheyen, G. et al. (2004) Outcome of testicular sperm recovery and ICSI in patients with non-obstructive azoospermia with a history of orchidopexy. Human Reproduction, 19, 2307 2312.
10. Lee, P.A. Coughlin, M.T. (2001) Fertility after bilateral cryptorchidism. evaluation by paternity, hormone, and semen data. Hormone Research, 55, 28 32.
11. Quinton, R., Duke, V.M., de Zoysa, P.A. et al. (1996) The neuroradiology of Kallmann's syndrome: a genotypic and phenotypic analysis. Journal of Clinical Endocrinology and Metabolism, 81, 3010 3017.
12. Zitzmann, M. Nieschlag, E. (2007) Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. Journal of Clinical Endocrinology and Metabolism, 92, 3844 3853.
13. Schopohl, J., Mehltretter, G., von Zumbusch, R. et al. (1991) Comparison of gonadotropin-releasing hormone and gonadotropin therapy in male patients with idiopathic hypothalamic hypogonadism. Fertility and Sterility, 56, 1143 1150.
14. Seftel, A. (2007) Testosterone replacement therapy for male hypogonadism: part III. Pharmacologic and clinical profiles, monitoring, safety issues, and potential future agents. International Journal of Impotence Research, 19, 2 24.
15. Rhoden, E.L. Morgentaler, A. (2004) Treatment of testosterone-induced gynecomastia with the aromatase inhibitor, anastrozole. International Journal of Impotence Research, 16, 95 97.
16. Wang, C., Nieschlag, E., Swerdloff, R. et al. (2008) Investigation, treatment and monitoring of late-onset hypogonadism in males, ISA, ISSAM, EAU, EAA and ASA recommendations. European Journal Endocrinology, 159, 507 514.
17. Behre, H.M. (2000) Testosterone therapy - effects on prostate and bone. Aging Male, 3, 196 202.
18. Rhoden, E.L. Morgentaler, A. (2006) Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy. International Journal of Impotence Research, 18, 201 205.
19. Raynaud, J.P. (2006) Prostate cancer risk in testosterone-treated men. Journal of Steroid Biochemistry and Molecular Biology, 102, 261 266.
20. Raivio, T., Falardeau, J., Dwyer, A. et al. (2007) Reversal of idiopathic hypogonadotropic hypogonadism. New England Journal of Medicine, 357, 863 873.
21. Bouloux, P.M., Nieschlag, E., Burger, H.G. et al. (2003) Induction of spermatogenesis by recombinant follicle-stimulating hormone (puregon) in hypogonadotropic azoospermic men who failed to respond to human chorionic gonadotropin alone. Journal of Andrology, 24, 604 611.
22. Bouloux, P., Warne, D.W., Loumaye, E. et al. (2002) Efficacy and safety of recombinant human follicle-stimulating hormone in men with isolated hypogonadotropic hypogonadism. Fertility and Sterility, 77, 270 273.
23. Jones, T.H. Darne, J.F. (1993) Self-administered subcutaneous human menopausal gonadotrophin for the stimulation of testicular growth and the initiation of spermatogenesis in hypogonadotrophic hypogonadism. Clinical Endocrinology, 38, 203 208.
24. Barrio, R., de Luis, D., Alonso, M. et al. (1999) Induction of puberty with human chorionic gonadotropin and follicle-stimulating hormone in adolescent males with hypogonadotropic hypogonadism. Fertility and Sterility, 71, 244 248.
25. European Metrodin HP Study Group. (1998) Efficacy and safety of highly purified urinary follicle-stimulating hormone with human chorionic gonadotropin for treating men with isolated hypogonadotropic hypogonadism. Fertility and Sterility, 70, 256 262.
26. Buchter, D., Behre, H.M., Kliesch, S. et al. (1998) Pulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism, a review of 42 cases. European Journal of Endocrinology, 139, 298 303.
27. Kulin, H.E., Samojlik, E., Santen, R. et al. (1981) The effect of growth hormone on the Leydig cell response to chorionic gonadotrophin in boys with hypopituitarism. Clinical Endocrinology, 15, 463 472.
28. Pitteloud, N., Hayes, F.J., Dwyer, A. et al. (2002) Predictors of outcome of long-term GnRH therapy in men with idiopathic hypogonadotropic hypogonadism. Journal of Clinical Endocrinology and Metabolism, 87, 4128 4136.
29. Liu, P.Y., Baker, H.W., Jayadev, V. et al. (2009) Induction of spermatogenesis and fertility during gonadotropin treatment of gonadotropin-deficient infertile men, predictors of fertility outcome. Journal of Clinical Endocrinology and Metabolism, 94, 801 808.
30. Raivio, T., Wikström, A.M. Dunkel, L. (2007) Treatment of gonadotrophins-deficient boys with recombinant human FSH, long-term observation and outcome. European Journal Endocrinology, 156, 105 111.
31. Zorn, B., Pfeifer, M., Virant-Klun, I. et al. (2005) Intracytoplasmic sperm injection as a complement to gonadotrophin treatment in infertile men with hypogonadotrophic hypogonadism. International Journal of Andrology, 28, 202 207.
32. Whitcomb, R.W. Crowley Jr., W.F. (1990) Diagnosis and treatment of isolated gonadotropin-releasing hormone deficiency in men. Journal of Clinical Endocrinology and Metabolism, 70, 3 7.
33. Schopohl, J. (1993) Pulsatile gonadotrophin releasing hormone versus gonadotrophin treatment of hypothalamic hypogonadism in males. Human Reproduction, 8 (Suppl. 2 175 179.
34. Liu, L., Banks, S.M., Barnes, K.M. et al. (1988) Two-year comparison of testicular response to pulsatile gonadotropin-releasing hormone and exogenous gonadotropins from the inception of therapy in men with isolated hypogonadotropic hypogonadism. Journal of Clinical Endocrinology and Metabolism, 67, 1140 1145. (Pubitemid 19012943)
35. Depenbusch, M., von Eckardstein, S., Simoni, M. et al. (2002) Maintenance of spermatogenesis in hypogonadotropic hypogonadal men with human chorionic gonadotropin alone. European Journal Endocrinology, 147, 617 624.
36. Piperno, A., Rivolta, M.R., D'Alba, R. et al. (1992) Preclinical hypogonadism in genetic hemochromatosis in the early stage of the disease: evidence of hypothalamic dysfunction. Journal of Endocrinological Investigation, 15, 423 428.
37. Siemons, L.J. Mahler, C.H. (1987) Hypogonadotropic hypogonadism in hemochromatosis: recovery of reproductive function after iron depletion. Journal of Clinical Endocrinology and Metabolism, 65, 585 587.
38. Cundy, T., Butler, J., Bomford, A. et al. (1993) Reversibility of hypogonadotropic hypogonadism associated with genetic hemochromatosis. Clinical Endocrinology, 38, 617 620.